As Trial Nears, Kaiser Flays Pfizer Neurontin Studies

Law360, New York (January 21, 2010, 7:04 PM EST) -- With a trial in the multidistrict litigation over Pfizer Inc.’s alleged off-label marketing of Neurontin just a month away, Kaiser Foundation Health Plan Inc. is attacking the credibility of Pfizer’s expert testimony, contending the doctors embraced sham clinical results when vouching for the drug’s effectiveness as a treatment for bipolar disorder and migraines.

Kaiser urged Judge Patti B. Saris of the U.S. District Court for the District of Massachusetts on Thursday to reject five of Pfizer’s experts, saying they suppressed negative results and relied on inferior,...
To view the full article, register now.